Study supports longer scope intervals post-polypectomy

This article originally appeared here.
Study Supports Longer Scope Intervals Post-Polypectomy
Study Supports Longer Scope Intervals Post-Polypectomy

(HealthDay News) -- For individuals who have had at least one adenoma removed at colonoscopy, the risk of developing colorectal cancer is greatly reduced up to five years later, according to a study published online June 23 in the Journal of Clinical Oncology.

Hermann Brenner, M.D., M.P.H., from the German Cancer Research Center in Heidelberg, and colleagues examined the risk of colorectal cancer based on time since adenoma removal at colonoscopy in 2,582 patients with a history of at least one adenoma removal and 1,798 matched controls who had never undergone large-bowel endoscopy.

The researchers found that the risk of colorectal cancer was reduced in patients who had undergone polypectomy compared to those without previous endoscopy, with adjusted odds ratios of 0.2 for polypectomy less than three years earlier, 0.4 for polypectomy three to five years earlier, and 0.9 for polypectomy six to 10 years earlier. The reduction in risk within five years of adenoma removal was consistently found in both genders and all age groups examined and regardless of the presence of high-risk polyps and polypectomy in the right colon. In addition, the risk was particularly reduced in those with left-sided colorectal cancer.

"Our study provides further support for suggestions that surveillance colonoscopy may be postponed to five to 10 years after detection and removal of low-risk adenomas and furthermore suggests possible prolongation of surveillance intervals to five years, even in the case of high-risk adenomas," Brenner and colleagues conclude.

Abstract
Full Text (subscription or payment may be required)

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs